$1.80
-0.11[-5.76%]
At close: Apr 19
$1.80
0[0.00%]
After Hours: 7:54PM EDT
ATAI Life Sciences
(NASDAQ:ATAI)ATAI Life Sciences Stock (NASDAQ:ATAI), Analyst Ratings, Price Targets, Predictions
ATAI Life Sciences NV has a consensus price target of $16.24, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Maxim Group, and HC Wainwright & Co. on April 4, 2024, April 3, 2024, and April 3, 2024. With an average price target of $7 between Cantor Fitzgerald, Maxim Group, and HC Wainwright & Co., there's an implied 288.89% upside for ATAI Life Sciences NV from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Maxim Group
HC Wainwright & Co.
EF Hutton
Credit Suisse
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ATAI Life Sciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2024 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 04/03/2024 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 233.33% | Maxim Group | Jason McCarthy | → $6 | Upgrade | Hold → Buy | Get Alert |
| 04/03/2024 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 733.33% | HC Wainwright & Co. | Patrick Trucchio | $20 → $15 | Maintains | Buy | Get Alert |
| 03/27/2024 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | $20 → $20 | Maintains | Buy | Get Alert |
| 01/04/2024 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 01/02/2024 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 733.33% | EF Hutton | Elemer Piros | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 733.33% | EF Hutton | Elemer Piros | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 400% | Credit Suisse | Judah Frommer | → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 03/31/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 733.33% | EF Hutton | Elemer Piros | → $15 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 400% | Credit Suisse | Judah Frommer | → $9 | Reiterates | → Outperform | Get Alert |
| 03/27/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 733.33% | EF Hutton | Elemer Piros | → $15 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 400% | Credit Suisse | Judah Frommer | $11 → $9 | Maintains | Outperform | Get Alert |
| 03/07/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 733.33% | EF Hutton | Elemer Piros | → $15 | Reiterates | → Buy | Get Alert |
| 01/19/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 1011.11% | HC Wainwright & Co. | Patrick Trucchio | $50 → $20 | Maintains | Buy | Get Alert |
| 01/09/2023 | ATAI | Buy Now | ATAI Life Sciences | $1.80 | 455.56% | Citigroup | Neena Bitritto-Garg | $20 → $10 | Maintains | Buy | Get Alert |
FAQ
What is the target price for ATAI Life Sciences (ATAI)?
The latest price target for ATAI Life Sciences (NASDAQ: ATAI) was reported by Cantor Fitzgerald on April 4, 2024. The analyst firm set a price target for $0.00 expecting ATAI to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ATAI Life Sciences (ATAI)?
The latest analyst rating for ATAI Life Sciences (NASDAQ: ATAI) was provided by Cantor Fitzgerald, and ATAI Life Sciences reiterated their overweight rating.
When was the last upgrade for ATAI Life Sciences (ATAI)?
The last upgrade for ATAI Life Sciences NV happened on April 3, 2024 when Maxim Group raised their price target to $6. Maxim Group previously had a hold for ATAI Life Sciences NV.
When was the last downgrade for ATAI Life Sciences (ATAI)?
There is no last downgrade for ATAI Life Sciences.
When is the next analyst rating going to be posted or updated for ATAI Life Sciences (ATAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ATAI Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ATAI Life Sciences was filed on April 4, 2024 so you should expect the next rating to be made available sometime around April 4, 2025.
Is the Analyst Rating ATAI Life Sciences (ATAI) correct?
While ratings are subjective and will change, the latest ATAI Life Sciences (ATAI) rating was a reiterated with a price target of $0.00 to $0.00. The current price ATAI Life Sciences (ATAI) is trading at is $1.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.